Explore

Trendline Trendline
Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets

Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets

Innovent Biologics and Pfizer Sign $10.5 Billion Oncology Deal Impacting Global Markets
Trendline Trendline
EnPlusOne Biosciences Appoints Jim Weissman to Board Amid RNA Synthesis Focus

EnPlusOne Biosciences Appoints Jim Weissman to Board Amid RNA Synthesis Focus

EnPlusOne Biosciences Appoints Jim Weissman to Board Amid RNA Synthesis Focus
Trendline Trendline
XL-protein Launches PASylANTA Therapeutics to Develop Long-Acting IL-1Ra Biobetters for Disease Management

XL-protein Launches PASylANTA Therapeutics to Develop Long-Acting IL-1Ra Biobetters for Disease Management

XL-protein Launches PASylANTA Therapeutics to Develop Long-Acting IL-1Ra Biobetters for Disease Management
Trendline Trendline
Viridian Therapeutics Secures Manufacturing Agreement with WuXi Biologics for Veligrotug

Viridian Therapeutics Secures Manufacturing Agreement with WuXi Biologics for Veligrotug

Viridian Therapeutics Secures Manufacturing Agreement with WuXi Biologics for Veligrotug
Trendline Trendline
WuXi Biologics Expands Global Manufacturing with New Drug Product Facility

WuXi Biologics Expands Global Manufacturing with New Drug Product Facility

WuXi Biologics Expands Global Manufacturing with New Drug Product Facility
Trendline Trendline
Viridian Therapeutics to Engage in June 2026 Investor Conferences, Highlighting Autoimmune and Rare Disease Focus

Viridian Therapeutics to Engage in June 2026 Investor Conferences, Highlighting Autoimmune and Rare Disease Focus

Viridian Therapeutics to Engage in June 2026 Investor Conferences, Highlighting Autoimmune and Rare Disease Focus
Trendline Trendline
Agilent Technologies Introduces Multi-Attribute Method Solution for BioPharma Quality Control

Agilent Technologies Introduces Multi-Attribute Method Solution for BioPharma Quality Control

Agilent Technologies Introduces Multi-Attribute Method Solution for BioPharma Quality Control
Trendline Trendline
Nu-Tek BioSciences Advances Animal-Free Raw Materials at BIO 2026, Supporting Biotech Innovation

Nu-Tek BioSciences Advances Animal-Free Raw Materials at BIO 2026, Supporting Biotech Innovation

Nu-Tek BioSciences Advances Animal-Free Raw Materials at BIO 2026, Supporting Biotech Innovation
Trendline Trendline
Agilent Technologies Introduces Multi-Attribute Method for Enhanced BioPharma Quality Control

Agilent Technologies Introduces Multi-Attribute Method for Enhanced BioPharma Quality Control

Agilent Technologies Introduces Multi-Attribute Method for Enhanced BioPharma Quality Control
Trendline Trendline
Nu-Tek BioSciences Leads Animal-Free Raw Materials Revolution at BIO 2026

Nu-Tek BioSciences Leads Animal-Free Raw Materials Revolution at BIO 2026

Nu-Tek BioSciences Leads Animal-Free Raw Materials Revolution at BIO 2026
Trendline Trendline
Insmed to Present at 2026 Goldman Sachs Healthcare Conference Highlighting Biopharmaceutical Innovations

Insmed to Present at 2026 Goldman Sachs Healthcare Conference Highlighting Biopharmaceutical Innovations

Insmed to Present at 2026 Goldman Sachs Healthcare Conference Highlighting Biopharmaceutical Innovations
Trendline Trendline
Viridian Therapeutics to Engage Investors at June 2026 Conferences, Highlighting Biotech Innovations

Viridian Therapeutics to Engage Investors at June 2026 Conferences, Highlighting Biotech Innovations

Viridian Therapeutics to Engage Investors at June 2026 Conferences, Highlighting Biotech Innovations